PL3791896T3 - Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu - Google Patents

Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu

Info

Publication number: PL3791896T3
Authority: PL; Poland
Prior art keywords: claudin; cancer; treatment; combination therapy; including antibodies
Prior art date: 2012-05-23

Application number

PL20194625.8T

Other languages

English (en)

Inventor

Ugur Sahin

Özlem TÜRECI

Rita Mitnacht-Kraus

Stefan Denis JACOBS

Magdalena Jadwiga UTSCH

Cornelia Adriana Maria HEINZ

Christiane Regina STADLER

Original Assignee

Astellas Pharma Inc.

Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-05-23

Filing date

2013-05-21

Publication date

2024-05-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3791896(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-05-21 Application filed by Astellas Pharma Inc., Tron - Translationale Onkologie An Der Universitätsmedizin Der Johannes Gutenberg- Universität Mainz Gemeinnützige Gmbh filed Critical Astellas Pharma Inc.

2024-05-13 Publication of PL3791896T3 publication Critical patent/PL3791896T3/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Microbiology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PL20194625.8T 2012-05-23 2013-05-21 Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu PL3791896T3 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/EP2012/002210 WO2013174403A1 (en)	2012-05-23	2012-05-23	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer

Publications (1)

Publication Number	Publication Date
PL3791896T3 true PL3791896T3 (pl)	2024-05-13

Family

ID=48483023

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL20194625.8T PL3791896T3 (pl)	2012-05-23	2013-05-21	Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu

Country Status (26)

Country	Link
US (2)	US20150132253A1 (pl)
JP (2)	JP6203831B2 (pl)
KR (4)	KR20240010757A (pl)
CN (2)	CN109172820B (pl)
AR (2)	AR091130A1 (pl)
AU (2)	AU2013265638B2 (pl)
BR (1)	BR112014028948B8 (pl)
CA (1)	CA2874032A1 (pl)
DK (2)	DK2852408T3 (pl)
ES (3)	ES2835073T3 (pl)
FI (1)	FI3791896T3 (pl)
HR (2)	HRP20240169T1 (pl)
HU (3)	HUE036000T2 (pl)
IL (2)	IL235607A0 (pl)
LT (3)	LT2852408T (pl)
MX (5)	MX2014014216A (pl)
NZ (2)	NZ701585A (pl)
PL (1)	PL3791896T3 (pl)
PT (3)	PT3791896T (pl)
RS (2)	RS65179B1 (pl)
RU (1)	RU2665321C2 (pl)
SG (2)	SG10201609772PA (pl)
SI (2)	SI3254695T1 (pl)
SM (2)	SMT202400061T1 (pl)
UA (1)	UA118013C2 (pl)
WO (2)	WO2013174403A1 (pl)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10254601A1 (de)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
WO2013174404A1 (en)	2012-05-23	2013-11-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
EP2852408B1 (en)	2012-05-23	2017-05-17	Ganymed Pharmaceuticals AG	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
KR102643443B1 (ko)	2012-11-13	2024-03-06	비온테크 에스이	클라우딘 발현 암 질환의 치료제
WO2014127785A1 (en)	2013-02-20	2014-08-28	Ganymed Pharmaceuticals Ag	Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en)	2013-03-18	2014-09-25	Ganymed Pharmaceuticals Ag	Therapy involving antibodies against claudin 18.2 for treatment of cancer
US20170081723A1 (en) *	2014-03-21	2017-03-23	Agency For Science, Technology And Research	Fusion Genes in Cancer
JP6743051B2 (ja)	2015-01-27	2020-08-19	ラヴァ・セラピューティクス・ベー・フェー	Ｃｄ１ｄを標的とする単一ドメイン抗体
WO2016180468A1 (en) *	2015-05-11	2016-11-17	Biontech Cell & Gene Therapies Gmbh	Claudin-18.2-specific immunoreceptors and t cell epitopes
BR112018075032A2 (pt)	2016-06-15	2019-03-26	Icahn School Of Medicine At Mount Sinai	proteínas de hemaglutinina do vírus influenza e seus uso
WO2018040537A1 (zh) *	2016-08-31	2018-03-08	南京凯地生物科技有限公司	人pd-1基因敲除的cldn18.2 特异性嵌合抗原受体t细胞的制备方法以及应用
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
US11254733B2 (en)	2017-04-07	2022-02-22	Icahn School Of Medicine At Mount Sinai	Anti-influenza B virus neuraminidase antibodies and uses thereof
WO2019132765A1 (en) *	2017-12-27	2019-07-04	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
US10150801B1 (en)	2017-12-27	2018-12-11	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
AU2019232762B2 (en) *	2018-03-08	2023-11-16	Phanes Therapeutics, Inc.	Anti-claudin 18.2 antibodies and uses thereof
WO2019219089A1 (en)	2018-05-18	2019-11-21	Bridge Health Bio-Tech Co., Ltd	Anti-claudin 18.2 antibodies and uses thereof
US12364746B2 (en)	2018-06-21	2025-07-22	Icahn School Of Medicine At Mount Sinai	Mosaic influenza virus hemagglutinin polypeptides and uses thereof
WO2020038404A1 (zh) *	2018-08-22	2020-02-27	瑞阳(苏州)生物科技有限公司	抗人claudin 18.2单克隆抗体及其应用
CN110857322A (zh) *	2018-08-22	2020-03-03	瑞阳(苏州)生物科技有限公司	抗人claudin 18.2单克隆抗体及其应用
WO2020060405A1 (en)	2018-09-19	2020-03-26	Lava Therapeutics B.V.	Dual acting cd1d immunoglobulin
US20220033491A1 (en) *	2018-09-30	2022-02-03	Cafa Therapeutics Limited	Combination therapy of cldn18 antibody and chemotherapy drugs
AU2019377109A1 (en) *	2018-11-08	2021-05-27	IN8bio, Inc.	Compositions and methods for treating cancer
AU2019415848A1 (en) *	2018-12-28	2021-08-19	Nanjing GenScript Biotech Co., Ltd.	Claudin18.2 binding moieties and uses thereof
WO2020135201A1 (zh) *	2018-12-28	2020-07-02	四川科伦博泰生物医药股份有限公司	一种抗体及其用途
TWI848090B (zh) *	2019-04-01	2024-07-11	大陸商江蘇恆瑞醫藥股份有限公司	密蛋白抗體及其應用
EP3959216A4 (en) *	2019-04-24	2023-01-11	Icahn School of Medicine at Mount Sinai	ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
EP3978532A4 (en) *	2019-05-24	2023-10-18	Sanyou Biopharmaceuticals Co., Ltd.	Novel cldn18.2 binding molecule
CN116041512A (zh) *	2019-07-12	2023-05-02	明济生物制药（北京）有限公司	Cldn18.2抗体及其用途
US10675332B1 (en)	2019-08-26	2020-06-09	Imunami Laboratories Pte. Ltd.	Recombinant polypeptides and methods of use thereof
WO2021115303A1 (zh) *	2019-12-11	2021-06-17	上海复宏汉霖生物技术股份有限公司	一种抗Claudin18.2单克隆抗体、其制备方法及用途
KR20220161316A (ko)	2020-03-30	2022-12-06	비온테크 에스이	Claudin-18.2를 표적화하는 rna 조성물
IL299748A (en)	2020-07-08	2023-03-01	Lava Therapeutics N V	Antibodies that bind PSMA and T gamma delta receptors
EP4420675A4 (en) *	2021-08-23	2025-10-15	Yichen Therapeutics Ltd	EPITOPE MODIFICATION
CN115057930B (zh) *	2021-09-03	2022-11-29	深圳市先康达生命科学有限公司	靶向人Claudin18.2蛋白的单克隆抗体及其应用
IL314678A (en)	2022-02-27	2024-10-01	Boehringer Ingelheim Int	Bispecific antibodies against cd277 and a tumor-antigen
JP2025534447A (ja)	2022-10-06	2025-10-15	バイオエヌテックエスエー	クローディン１８．２を標的とするｒｎａ組成物
WO2024074211A1 (en)	2022-10-06	2024-04-11	BioNTech SE	Rna compositions targeting claudin-18.2
WO2024199673A1 (en)	2023-03-31	2024-10-03	Università Degli Studi Di Verona	Methods for predicting and improving therapeutic efficacy of cancer treatments and methods for cancer prognosis
WO2025121445A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2
WO2025120866A1 (en)	2023-12-08	2025-06-12	Astellas Pharma Inc.	Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
FR2697752B1 (fr) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Compositions antitumorales contenant des dérivés du taxane.
US5595756A (en) *	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
KR100857943B1 (ko)	2000-11-30	2008-09-09	메다렉스, 인코포레이티드	인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
PT1558648E (pt)	2002-10-17	2012-04-23	Genmab As	Anticorpos monoclonais humanos contra cd20
KR20060134216A (ko) *	2004-04-16	2006-12-27	에미스페어 테크놀로지스, 인코포레이티드	활성제 전달을 위한 8-(2-히드록시페녹시)옥틸디에탄올아민및 그의 염
AU2006288348B2 (en) *	2005-09-08	2012-05-03	Medinet Co., Ltd.	Method for activation treatment of antigen-presenting cell
EP1790664A1 (en) *	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) *	2007-05-29	2008-12-03	Ganymed Pharmaceuticals AG	Monoclonal antibodies against Claudin-18 for treatment of cancer
WO2008152822A1 (ja) *	2007-06-15	2008-12-18	Medinet Co., Ltd.	医薬
JP5596559B2 (ja) *	2008-01-28	2014-09-24	メディミューンリミテッド	安定化アンジオポエチン２抗体とその用途
AU2009273540A1 (en) *	2008-07-25	2010-01-28	Merck Patent Gmbh	Method of determination of receptor binding saturation effected by monoclonal antibodies
WO2010141093A2 (en) *	2009-06-04	2010-12-09	The University Of Maryland, Baltimore	Co-signaling methods for treating cancers
WO2011090005A1 (ja) *	2010-01-19	2011-07-28	協和発酵キリン株式会社	大腸癌の治療用医薬および治療方法

2012
- 2012-05-23 WO PCT/EP2012/002210 patent/WO2013174403A1/en not_active Ceased
2013
- 2013-05-21 DK DK13724523.9T patent/DK2852408T3/en active
- 2013-05-21 WO PCT/EP2013/001504 patent/WO2013174510A1/en not_active Ceased
- 2013-05-21 PT PT201946258T patent/PT3791896T/pt unknown
- 2013-05-21 KR KR1020247001045A patent/KR20240010757A/ko not_active Ceased
- 2013-05-21 PL PL20194625.8T patent/PL3791896T3/pl unknown
- 2013-05-21 KR KR1020217006323A patent/KR102625189B1/ko active Active
- 2013-05-21 NZ NZ701585A patent/NZ701585A/en not_active IP Right Cessation
- 2013-05-21 PT PT171711690T patent/PT3254695T/pt unknown
- 2013-05-21 NZ NZ725347A patent/NZ725347A/en unknown
- 2013-05-21 ES ES17171169T patent/ES2835073T3/es active Active
- 2013-05-21 PT PT137245239T patent/PT2852408T/pt unknown
- 2013-05-21 KR KR1020257028324A patent/KR20250133804A/ko active Pending
- 2013-05-21 CN CN201811066117.4A patent/CN109172820B/zh active Active
- 2013-05-21 HU HUE13724523A patent/HUE036000T2/hu unknown
- 2013-05-21 RS RS20240147A patent/RS65179B1/sr unknown
- 2013-05-21 SI SI201331818T patent/SI3254695T1/sl unknown
- 2013-05-21 SG SG10201609772PA patent/SG10201609772PA/en unknown
- 2013-05-21 JP JP2015513044A patent/JP6203831B2/ja active Active
- 2013-05-21 CA CA2874032A patent/CA2874032A1/en active Pending
- 2013-05-21 HU HUE17171169A patent/HUE054214T2/hu unknown
- 2013-05-21 RU RU2014152115A patent/RU2665321C2/ru active
- 2013-05-21 HU HUE20194625A patent/HUE065848T2/hu unknown
- 2013-05-21 HR HRP20240169TT patent/HRP20240169T1/hr unknown
- 2013-05-21 DK DK20194625.8T patent/DK3791896T5/da active
- 2013-05-21 MX MX2014014216A patent/MX2014014216A/es active IP Right Grant
- 2013-05-21 US US14/401,899 patent/US20150132253A1/en not_active Abandoned
- 2013-05-21 LT LTEP13724523.9T patent/LT2852408T/lt unknown
- 2013-05-21 CN CN201380026482.1A patent/CN104379166B/zh active Active
- 2013-05-21 ES ES20194625T patent/ES2971318T3/es active Active
- 2013-05-21 RS RS20201449A patent/RS61127B1/sr unknown
- 2013-05-21 ES ES13724523.9T patent/ES2637416T3/es active Active
- 2013-05-21 SI SI201332076T patent/SI3791896T1/sl unknown
- 2013-05-21 KR KR1020147036040A patent/KR102233344B1/ko active Active
- 2013-05-21 SG SG11201406977TA patent/SG11201406977TA/en unknown
- 2013-05-21 FI FIEP20194625.8T patent/FI3791896T3/fi active
- 2013-05-21 UA UAA201413810A patent/UA118013C2/uk unknown
- 2013-05-21 LT LTEP17171169.0T patent/LT3254695T/lt unknown
- 2013-05-21 LT LTEP20194625.8T patent/LT3791896T/lt unknown
- 2013-05-21 BR BR112014028948A patent/BR112014028948B8/pt active IP Right Grant
- 2013-05-21 SM SM20240061T patent/SMT202400061T1/it unknown
- 2013-05-21 AU AU2013265638A patent/AU2013265638B2/en active Active
- 2013-05-21 SM SM20200675T patent/SMT202000675T1/it unknown
- 2013-05-22 AR ARP130101784 patent/AR091130A1/es not_active Application Discontinuation
2014
- 2014-11-10 IL IL235607A patent/IL235607A0/en active IP Right Grant
- 2014-11-21 MX MX2020011782A patent/MX2020011782A/es unknown
- 2014-11-21 MX MX2020011780A patent/MX2020011780A/es unknown
- 2014-11-21 MX MX2019013723A patent/MX2019013723A/es unknown
- 2014-11-21 MX MX2020011771A patent/MX2020011771A/es unknown
2017
- 2017-08-30 JP JP2017165303A patent/JP6490764B2/ja active Active
2018
- 2018-02-27 AU AU2018201391A patent/AU2018201391B2/en active Active
- 2018-03-01 US US15/909,577 patent/US20180258180A1/en not_active Abandoned
2020
- 2020-11-23 HR HRP20201859TT patent/HRP20201859T1/hr unknown
- 2020-12-09 IL IL279330A patent/IL279330A/en unknown
2022
- 2022-05-17 AR ARP220101320A patent/AR125906A2/es unknown

Also Published As

Publication number	Publication date
ES2971318T3 (es)	2024-06-04
MX2020011771A (es)	2020-11-24
MX2020011782A (es)	2020-11-24
RU2014152115A (ru)	2016-07-20
BR112014028948B1 (pt)	2019-04-16
PT3791896T (pt)	2024-02-12
DK3791896T5 (da)	2024-08-19
HRP20240169T1 (hr)	2024-04-26
CN104379166B (zh)	2018-10-12
WO2013174510A1 (en)	2013-11-28
AU2013265638B2 (en)	2018-03-01
SG10201609772PA (en)	2017-01-27
AR125906A2 (es)	2023-08-23
ES2835073T3 (es)	2021-06-21
SI3254695T1 (sl)	2021-01-29
PT2852408T (pt)	2017-08-25
AU2018201391B2 (en)	2019-12-05
PT3254695T (pt)	2020-12-11
KR20250133804A (ko)	2025-09-08
LT3254695T (lt)	2020-12-28
NZ701585A (en)	2016-10-28
HUE065848T2 (hu)	2024-06-28
KR20150028777A (ko)	2015-03-16
CN109172820A (zh)	2019-01-11
KR20210025730A (ko)	2021-03-09
HUE036000T2 (hu)	2018-06-28
AR091130A1 (es)	2015-01-14
SMT202000675T1 (it)	2021-01-05
SG11201406977TA (en)	2014-12-30
SI3791896T1 (sl)	2024-04-30
HRP20201859T1 (hr)	2021-04-02
UA118013C2 (uk)	2018-11-12
DK2852408T3 (en)	2017-09-11
HUE054214T2 (hu)	2021-08-30
MX2019013723A (es)	2020-07-20
CN109172820B (zh)	2023-06-20
WO2013174403A1 (en)	2013-11-28
IL235607A0 (en)	2015-01-29
AU2018201391A1 (en)	2018-03-22
CA2874032A1 (en)	2013-11-28
KR20240010757A (ko)	2024-01-24
KR102233344B1 (ko)	2021-03-30
LT3791896T (lt)	2024-03-12
BR112014028948A2 (pt)	2016-10-25
JP6203831B2 (ja)	2017-09-27
US20180258180A1 (en)	2018-09-13
JP2018035155A (ja)	2018-03-08
JP6490764B2 (ja)	2019-03-27
FI3791896T3 (fi)	2024-02-01
BR112014028948A8 (pt)	2018-12-26
LT2852408T (lt)	2017-09-25
HK1208152A1 (en)	2016-02-26
BR112014028948B8 (pt)	2019-09-03
RS61127B1 (sr)	2020-12-31
AU2013265638A1 (en)	2014-11-20
MX2020011780A (es)	2020-11-24
KR102625189B1 (ko)	2024-01-16
ES2637416T3 (es)	2017-10-13
RS65179B1 (sr)	2024-03-29
NZ725347A (en)	2018-07-27
DK3791896T3 (da)	2024-02-12
RU2665321C2 (ru)	2018-09-04
JP2015522543A (ja)	2015-08-06
MX2014014216A (es)	2015-06-23
US20150132253A1 (en)	2015-05-14
CN104379166A (zh)	2015-02-25
SMT202400061T1 (it)	2024-03-13
IL279330A (en)	2021-01-31

Publication	Publication Date	Title
IL279330A (en)	2021-01-31	Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer
IL276434A (en)	2020-09-30	Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer
IL282953A (en)	2021-06-30	Agents for treatment of claudin expressing cancer diseases
IL240060A0 (en)	2015-09-24	Treatment involving antibodies against claudin 2. 18 for the treatment of cancer
IL239981B1 (en)	2023-05-01	Combined therapy involving antibodies against claudin 18.2 for the treatment of cancer
SMT201700387T1 (it)	2017-09-07	Terapia di combinazione implicante anticorpi contro claudina 18.2 per il trattamento del cancro
SMT202200458T1 (it)	2023-01-13	Terapia combinata con anticorpi contro la claudina 18.2 per il trattamento del cancro
SI2976360T1 (sl)	2020-04-30	Terapija, ki vključuje protitelesa proti Klavdinu 18.2 za zdravljenje raka
DK3725810T3 (da)	2022-07-25	Kombinationterapi, der involverer antistoffer mod claudin 18.2 til behandling af cancer